相关实验视频

Updated: May 3, 2026

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

尤金醇抑制血小板激活,并减轻人类和小鼠模型中的肺血栓栓塞

Wei-Chieh Huang¹, Lan-Hsin Shu², Yu-Ju Kuo¹

¹Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.

International journal of molecular sciences

|February 24, 2024

概括

尤根醇有效抑制血小板激活和聚合,对于心血管疾病 (CVD) 管理至关重要. 这种天然化合物针对特定的信号通路,为心血管疾病提供潜在的治疗益处.

科学领域:

药理学药理学是指药理学的学科.
生物化学生物化学
心血管研究研究心血管研究

背景情况:

血小板在心血管疾病 (CVD) 发病过程中发挥着至关重要的作用.
缓解血小板激活对于管理心血管疾病至关重要.
来自丁香油的尤根醇具有已知的药用特性.

研究的目的:

研究eugenol影响人类血小板激活的机制.
评估eugenol作为治疗心血管疾病的治疗剂的潜力.

主要方法:

评估了eugenol对2μM的原和酸 (AA) 诱导的血小板聚合的影响.
测量了eugenol对ATP释放,P-选择因表达和细胞内 ([Ca2+]i) 的影响.
分析了eugenol对关键信号级联 (PLCγ2/PKC,PI3K/Akt,MAPK,cPLA2/TxA2) 和酸化事件的抑制.
在ADP诱导的血栓形成的小鼠模型中评估了eugenol的疗效.

主要成果:

欧原醇抑制了由原和AA诱导的血小板聚合,但不是由血栓或U46619诱导的聚合.
欧原醇调节的ATP释放,P-选择因表达和[Ca2+]i.
尤根醇抑制了由原诱导的PLCγ2/PKC,PI3K/Akt和cPLA2/TxA2信号通路,并选择性地抑制了由AA诱导的cPLA2/TxA2酸化.
在体内,尤根醇可以减少肺血管中的血小板血栓,而不会增加出血时间.

结论:

尤根醇通过向PLCγ2-PKC和cPLA2-TxA2信号级联,强烈抑制血小板激活和聚合.
尤根醇表明选择性抑制特定的血小板激活通路.
这些发现强调了eugenol在治疗心血管疾病方面的潜在治疗价值.

关键词:

这就是MAPKK的意思.在PI3K/Akt/GSK-3β中.在PLCγ2PKCC中.cPLA2/TxA2 的情况.尤金诺醇是一种人类血小板是人类的血小板.肺动脉血栓形成肺动脉血栓形成

更多相关视频

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

A Porcine Model of Acute Autologous Pulmonary Embolism

A Porcine Model of Acute Autologous Pulmonary Embolism

Published on: September 6, 2024

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...